TABLE 4. Cluster Specific Outcomes for Longitudinal Study.
Study Group |
||||
---|---|---|---|---|
Cluster | Outcomes | Clinical (n = 10) |
Sputum (n = 8) |
Significance |
1: Obese female | Δ Inhaled corticosteroid dose*/μg per day (SEM) | −400 (328) | −462 (271) | 0.89 |
Severe exacerbation frequency over 12 mo (SEM) | 1.40 (0.78) | 1.50 (0.80) | 0.93 | |
Number commenced on oral corticosteroids | 2 | 1 | 0.59 | |
Clinical (n = 15) | Sputum (n = 24) | |||
|
||||
2: Inflammation predominant | Δ Inhaled corticosteroid dose*/μg per day (SEM) | +753 (334) | +241 (233) | 0.22 |
Severe exacerbation frequency over 12 mo (SEM) | 3.53 (1.18) | 0.38 (0.13) | 0.002 | |
Number commenced on oral corticosteroids | 2 | 9 | 0.17 | |
Clinical (n = 7) | Sputum (n = 4) | |||
|
||||
3: Early symptom predominant | Δ Inhaled corticosteroid dose*/μg per day (SEM) | +1,429 (429) | −400 (469) | 0.022 |
Severe exacerbation frequency over 12 mo (SEM) | 5.43 (1.90) | 2.50 (0.87) | 0.198 | |
Number commenced on oral corticosteroids | 6 | 0 | Undefined |
Expressed as equivalent dose of beclomethasone.
A comparison of prespecified asthma outcomes between the two management protocols analyzed according to cluster allocation of subjects at study entry.